# The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

> **NCT01137799** · PHASE1 · TERMINATED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 47 (actual)

## Conditions studied

- Schizophrenia
- Alzheimer's Disease
- Cognition Disorders

## Interventions

- **DRUG:** JNJ-39393406
- **DRUG:** placebo
- **DRUG:** JNJ-39393406
- **DRUG:** JNJ-39393406
- **DRUG:** JNJ-39393406
- **DRUG:** JNJ-39393406

## Key facts

- **NCT ID:** NCT01137799
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** —
- **Final completion:** 2011-03
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Efficacy signals were insufficiently strong to justify recruitment of additional patients.
- **Last updated:** 2012-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137799, "The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01137799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*